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Objective: This study investigated the clinical features and the
postoperative prognosis in patients with small cell lung cancer
(SCLC).
Subjects: In this study, 1373 patients underwent a resection of lung
cancer between 1980 and 2006. There were 53 patients (3.8%) with
SCLC among them. They were divided into two groups, including
the early (1980–1993) and late (1994–2004) period groups. The clin-
icopathologic features and the results of surgery were investigated.
Results: The early and late period groups consisted of 22 and 31
patients, respectively. The pathologic stage of early group was stage
IA in five, IB in three, II in five, IIIA in five, and IIIB in four patients
and of late group was stage 0 in two, IA in three, IB in three, II in
seven, IIIA in nine, and IIIB in seven patients. The survival rates 5
years after surgery were 8.7 and 38.3%, respectively. Preoperative
chemotherapy with CAV (cyclophosphamide, doxorubicin, vincris-
tine) or PE (cis-diamminedichloroplatinum  VP16) regimens was
performed in 11 patients in the early period group. The treatment
response was evaluated as a partial response in eight patients and
stable disease in three. In the late period group, cis-diamminedichlo-
roplatinum/carboplatin VP16 therapies were administered to eight
patients. The treatment response was evaluated as a complete re-
sponse in two patients and partial response in six.
Conclusion: Surgery could be performed with a curative intent in
only a small number of patients with limited disease of SCLC or
significant nodal response after chemotherapy. The prognosis after
surgery was not satisfactory, especially in the early period. It was
considered to be partly because of differences in the regimens and
dose intensity of chemotherapy between the early and late period.
Key Words: Small cell lung cancer, Pulmonary resection, Surgical
outcome, Chemotherapy.
(J Thorac Oncol. 2009;4: 964–968)
Lung cancer is still a leading cause of cancer-related mor-tality in many industrialized countries.1,2 It remains a
considerable public health problem and reducing the mortal-
ity of lung cancer remains an important issue. Small cell lung
cancer (SCLC) represents 10 to 20% of all lung cancer in the
United States and Europe.3,4 The incidence of SCLC has been
decreasing over the last several years and the incident rate
declined among males, but it is continuing to increase among
females.5 SCLC is more aggressive lung cancer than non-
small lung cancer, because of its rapid growth and early
tendency to spread to distant organs. SCLC is one of the most
sensitive tumors to chemotherapy and radiotherapy, which
can give patients a chance to prolong their survival.6 More
than 80% of patients with SCLC can respond to chemother-
apy alone, but the 2-year overall survival rate is less than
20%.7,8 This may be associated with frequent local relapse
and distant metastases.
Previously, surgery is not thought to be indicated for
SCLC, and surgical treatment is limited as an option for very
early stage disease and its clinical significance was still
uncertain for small cell carcinoma. Generally, surgery plays
little role in the management of small-cell lung cancer, but
the exceptions are a small number of patients those who are
diagnosed at stage I (when the cancer is confined to the lung
without any spread to the lymph nodes). Recent studies have
reported that multimodality treatment involving surgery
achieved a good prognosis in SCLC patients with limited-
stage disease, thus suggesting the importance of surgery with
a curative intent.9,10 Nevertheless, surgery alone is not con-
sidered to be sufficient to achieve a complete cure. The
present study investigated the results of surgical treatment for
patients with SCLC.
PATIENTS AND METHODS
The hospital records of 1373 consecutive patients who
underwent a resection of lung cancer between 1980 and 2006
were reviewed. Among them, 53 patients (3.8%) had SCLC.
Those patients were divided into two groups, early (n  22)
(1980–1993) and late (n  31) (1994–2004) period groups
and their clinicopathologic features and the results of surgery
were investigated. Because granulocyte-colony stimulating
factor (G-CSF) and serotonin-antagonizing antiemetic agent
has become available since 1994, the chemotherapeutic reg-
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imens were thus changed. Therefore, the patient groups were
divided into those before and after 1994.
The preoperative assessments included chest roentgen-
ography, computed tomography of the chest and upper abdo-
men, bronchoscopy, and bone scintigraphy. Magnetic reso-
nance imaging of the brain was used only in the late period.
The patients’ records including the clinical data, preoperative
examination results, details of the surgical operation, his-
topathologic findings, and tumor, node, metastasis stages of
all patients were also reviewed. Induction chemotherapy was
planned for the patients if small cell carcinoma was diag-
nosed preoperatively, but except for patients at stage I. The
regimen of induction chemotherapy was mitomycin, CAV
(cyclophosphamide, doxorubicin, vincristine), and PE (cis-
diamminedichloroplatinum [CDDP]  VP16 [etoposide]) in
the early period. In the late period, induction chemotherapy
was performed with the PE regimen. CDDP was administered
with 40 mg/m2 on day 1 and VP16 (100 mg/body) was given
on days 1, 2, and 3 in the early period. Nevertheless, CDDP
was administered with 80 mg/m2 on day 1 and the combined
use of VP16 (100 mg/m2) on days 1, 2, and 3 in the late
period. In the both periods, two to three cycles of induction
chemotherapy was performed. The candidates for surgical
resection in both periods were (1) patients at stages IA and
IB, or (2) patients with completely resectable tumor after
induction chemotherapy.
All resected specimens including the primary tumor
and systematically resected hilar and mediastinal lymph
nodes were examined for tumor histology and the extent of
lymph node metastases. The histopathologic findings were
classified according to the World Health Organization crite-
ria, and the UICC tumor, node, metastasis staging system was
employed.11,12 The postoperative chemotherapy was per-
formed in the same manner as induction chemotherapy if the
patient condition after surgery was well tolerable against the
treatment, or unless patients refused additional chemother-
apy. Follow-up information was obtained from all patients
through office visits or telephone interviews with the patient,
a relative, or their primary physicians. The patients were eval-
uated every 3 months by chest roentgenography, and chest
computed tomography scan and bone scintigraphy were ob-
tained every 6 months for the first 2 years after surgery, and
annually thereafter. The mean observation time was 3.2 years.
The survival curve was calculated by the Kaplan-Meier
method and compared by using the log-rank test for the
univariate analysis. Categorical variables were compared by
Fisher’s exact test. The differences were considered to be
significant, if the p value was less than 0.05. The Statview V
software program (Abacus Concept, Berkeley, CA) was used
for all statistical analyses.
RESULTS
In this study, 1373 patients underwent a resection of
lung cancer between 1980 and 2006. Among them, 53 pa-
tients (3.8%) were with SCLC, who were divided into two
groups, the early (1980–1993) and late (1994–2004) period
groups and their clinicopathologic features and the results of
surgery were investigated. The early and late period groups
consisted of 22 and 31 patients, respectively (Table 1). A
preoperative diagnosis of small cell carcinoma was obtained
in 12 patients (54.5%) in the early period and 13 patients
(41.9%) in the late period. The clinical stage of early group
was IA in six, IB in five, II in one, IIIA in eight, and IIIB in two
patients and that of late group was IA in seven, IB in three, II in
three, IIIA in 12, and IIIB in six patients. Induction chemother-
apy with CAV or PE regimens was performed in 11 patients in
the early period group (Table 2). The treatment response was
evaluated as a partial response in eight patients and stable
disease in three. In the late period group, PE or CBDCA 
VP16 therapies were administered to eight patients before sur-
gery. The treatment response was evaluated as a complete
response in two patients and partial response in six. Five pa-
tients underwent neither induction nor adjuvant chemother-
apy because of their refusal to undergo chemotherapy in two,
renal failure in two, and interstitial pneumonia in one patient.
The operative procedures included 7 pneumonectomies
(31.8%), 12 lobectomies (54.5%), 2 segmentectomies (9.1%),
and 1 partial resection in the early period (4.5%), and 8
pneumonectomies (25.8%), 20 lobectomies (64.5%), 1 seg-
mentectomy (3.2%), and 2 partial resections in the late period
(6.5%). The limited resections (partial resection and segmen-
tectomy) with mediastinal lymph nodes sampling were per-
TABLE 1. Characteristics of Small Cell Lung Cancer Patients
in the Early Period and the Late Period
Characteristics
Early Period (n  22) Late Period (n  31)
No. of Patients (%) No. of Patients (%)
Age (mean yr) 65.5 67.6
Male 19 (86.4) 24 (77.4)
Preoperative diagnosis of
small cell lung cancer
12 (54.5) 13 (41.9)
Preoperative chemotherapy 11 (50.0) 8 (25.8)
Postoperative
chemotherapy
14 (63.6) 23 (74.2)
Preoperative radiotherapy 0 3 (9.7)
Postoperative radiotherapy 3 (13.6) 4 (12.9)
Clinical stage
IA 6 (27.3) 7 (22.6)
IB 5 (22.7) 3 (9.7)
II 1 (4.5) 3 (9.7)
IIIA 8 (36.4) 12 (38.7)
IIIB 2 (9.5) 6 (19.4)
Operative procedure
Pneumonectomy 7 (31.8) 8 (25.8)
Lobectomy and
bilobectomy
12 (54.5) 20 (64.5)
Segmentectomy 2 (9.1) 1 (3.2)
Partial resection 1 (4.5) 2 (6.5)
Pathologic stage
0 0 2 (6.5)
IA 5 (22.7) 3 (9.7)
IB 3 (13.6) 3 (9.7)
II 5 (22.7) 7 (22.6)
IIIA 5 (22.7) 9 (29.0)
IIIB 4 (18.9) 7 (22.5)
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formed as part of multimodality therapy. There were no signif-
icant differences in operative procedures between the early and
late period. The pathologic stage of the early group was stage IA
in five, IB in three, II in five, IIIA in five, and IIIB in four
patients, and of late group was stage 0 in two, IA in three, IB in
three, II in seven, IIIA in nine, and IIIB in seven patient. The
postoperative 5-year survival rates of early and late groups were
8.7 and 38.3%, respectively. The prognosis was significantly
poorer in the early group than the late group (Figure 1). Accord-
ing to the stage, the 5-year survival rates were 55.0 and 38.8%
in stages I and III, respectively. In comparison with other
histologies, the 5-year survival rates were 63.8, 47.3, 56.3, and
34.3% in adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and small cell carcinoma, respectively (Figure 2).
Adenocarcinoma showed a significantly better prognosis than
small cell carcinoma (p  0.01). No significant differences in
the survival curves were observed between small cell carcinoma
and large cell carcinoma or between small cell carcinoma and
squamous cell carcinoma.
DISCUSSION
SCLC is the most aggressive subtype of lung cancer
with a rapid tumor doubling time and early development of
widespread metastases. Combination chemotherapy remains
the mainstay of treatment for both limited-stage and exten-
sive-stage SCLC. In general, the administration of etoposide
and cisplatin plus chest radiotherapy for patients with good
performance status and limited-stage disease provides a com-
plete-response rate of approximately 80%, a median survival
of 17 to 23 months and a 5-year survival of 12 to 25%.13,14
Therefore, a surgical resection was not indicated for SCLC at
diagnosis, because radiotherapy was reported to superior to
surgery as a local therapy previously.15,16 However, Shields
et al.17 reported that 5-year survival rates of stages IA, IB,
IIA, IIB, and III after curative resection were 59.9, 27.9, 31.3,
9.0, and 3.6%, respectively, thus, suggesting that the initial
surgical resection may play a role in the curative treatment for
stage I disease.
Previously Lad et al.18 reported that the addition of
pulmonary resection after induction chemotherapy as multimo-
darity treatment did not improve the survival for chemotherapy
responders with SCLC in prospective randomized trial. Never-
theless, the chemotherapy regimen was CAV in their study,
and chemotherapy was thereafter replaced by CDDP VP16
as a front line chemotherapy. Recently a small population
(5–10%) of SCLC patients was diagnosed at stages IA and IB
and their 5-year survival was 20 to 40% after a surgical
resection.9,10 These studies have also reported that multidis-
ciplinary treatment involving chemotherapy and surgery
achieved a favorable prognosis in the SCLC patients without
mediastinal lymph node metastasis, thus suggesting the im-
portance of surgery.19,20 The theoretical advantages of surgi-
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FIGURE 1. Comparison of the overall survival curves of pa-
tients between the early period and the late period. The 5-year
survival rates were 8.7 and 38.8% in the early period and the
late period, respectively. The prognosis was significantly better
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FIGURE 2. Overall survival curves of patients with lung
cancer according to the histology in the late period. The
5-year survival rates were 63.8, 47.3, 56.3, and 34.3% in
adenocarcinoma, squamous cell carcinoma, large cell carci-
noma, and small cell carcinoma, respectively. The prognosis
was significantly better in adenocarcinoma than small cell
carcinoma (p  0.01). There were no significant differences
between small cell carcinoma and large cell carcinoma or
between small cell carcinoma and squamous cell carcinoma.
Ad, adenocarcinoma; Sq, squamous cell carcinoma; large,
large cell carcinoma; Sm, small cell carcinoma.
TABLE 2. Response to Preoperative Chemotherapy
Characteristics n CR PR SD
Early period (n  11)
MMC 1 1
CAV 2 2
CDDP  VP16 6 4 2
CBDCA  VP16 2 2
Late period (n  8)
CDDP  VP16 6 2 4
CBDCA  VP16 2 2
CDDP was administered with 40 mg/m2 on day 1 and VP16 (100 mg/body) was
given on days 1, 2, and 3 in the early period. In contrast, CDDP was administered with
80 mg/m2 on day 1 and the combined use of VP16 (100 mg/m2) on days 1, 2, and 3 in
the late period.
MMC, mitomycin; CAV, cyclophosphamide, doxorubicin, vincristine; CDDP,
cisplatine; CBDCA, carboplatin; VP16, etoposide; CR, complete response; PR, partial
response.
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without harmful effect to the bone marrow and to allow
accurate disease staging. In stages II and III patients, chemo-
therapy and radiotherapy are mainly recommended; however,
some studies indicate that surgery combined with adjuvant
chemotherapy improves the prognosis.19,20
In the present study, the 5-year survival rates were
55.0% at stage I, thus suggesting the efficacy of surgery in
combination of chemotherapy for patients without lymph
node metastasis. When the postoperative survival of SCLC
was compared with the other histologies of lung cancer, the
patients with adenocarcinoma had a better prognosis than
SCLC but no significant differences were observed among
the other histologic types (Figure 3). The candidates for a
surgical resection with stages II-III disease in the late period
included those who were chemotherapy responders with a
completely resectable tumor. The overall survival at 3 and 5
years after surgery in SCLC were 57.2 and 38.3%, respec-
tively, and the median survival time was 46 months in the late
period (Figure 1). However, the 3-year survival and the
median survival time of patients, who underwent CDDP 
VP16 with concurrent radiotherapy, were reported to be 30 to
40% and 20 to 23 months in the limited-disease SCLC.21,22
Therefore, this study suggested that surgery could play a
potential role in the multimodality therapy for patients with
the limited-disease SCLC.
In the present study, the results of induction chemo-
therapy were better in the late period than the early period.
The postoperative results in the late period group were also
significantly better than those in the early period group. In the
early period study, 21 (95.5%) of 22 patients underwent
induction chemotherapy or adjuvant chemotherapy. In the
late period group, 26 (83.9%) of 31 patients were adminis-
tered induction chemotherapy or adjuvant chemotherapy.
There were no significant differences in patient characteris-
tics and operative procedures between the early and the late
period. Therefore, the difference in the prognosis after surgery
might be because of the difference in the chemotherapeutic
regimen. In the late period group, more potent chemotherapy
was performed, because G-CSF and serotonin-antagonizing an-
tiemetic agents could be available in the late period. Myelo-
suppression is the major toxicity in platinum-based chemo-
therapy and leukocytopenia is preventable in most cases.
Nevertheless, it is possible to recover rapidly after the ad-
ministration of G-CSF in most patients. G-CSF plays an
important role in dose intensification of the chemotherapy for
in SCLC.23 CDDP is well known to be one of highly eme-
togenic chemotherapeutic agents. Emesis is one of dose
limiting factors and a major obstacle for continuous chemo-
therapy. The administration of serotonin receptor antagonists
for preventive therapy improves the management of chemo-
therapy-induced nausea and vomiting significantly.24 The
intensive chemotherapy combined with surgery may contrib-
ute to a better prognosis. This retrospective study covered a
period of longer than 20 years, during which time the image
diagnostic technology and perioperative management for
lung cancer both dramatically improved. As a result, a time
bias should also be considered to be another factor which
influenced their prognosis, because the medical eras remark-
ably differed between the two periods of the cohort.
The preoperative diagnosis of the histology is impor-
tant, because the treatment strategy for SCLC is different
from that for non-small lung cancer. Nevertheless, a periph-
eral lung tumor is not easy to diagnose precisely. In the
present study, approximately half of the patients yielded a
histologic diagnosis before surgery. The evaluation of medi-
astinal lymph node metastasis is also necessary to determine
the treatment strategy and decide the indication for surgery. A
recent study demonstrated the useful role of positron emis-
sion tomography to eliminate node positive disease, because
lymph node metastasis is a strong prognostic factor.25 Endo-
bronchial ultrasound guided needle and mediastinoscopy also
provides histologic proof of mediastinal downstaging after
induction chemotherapy with high diagnostic accuracy.26,27
Therefore, patients with SCLC at stage I can receive a
benefit from a surgical resection combine with platinum-
based chemotherapy. The patients with resectable SCLC at
stages II and IIIA who respond to induction chemotherapy
may have a chance of achieving a cure by surgery, but further
prospective clinical trials are necessary.
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